Wegovy vs Mounjaro: Clinical Differences at 1.7mg Dose
Understanding 1.7mg Wegovy Equivalent in Mounjaro Dosing
When comparing 1.7mg Wegovy to Mounjaro, the fundamental difference lies in their mechanisms of action rather than direct dose equivalency. Wegovy contains semaglutide, a GLP-1 receptor agonist, whilst Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. At the 1.7mg stage of Wegovy treatment (weeks 13-16), patients are approaching their maintenance phase, making this comparison particularly relevant for long-term treatment planning. EverydayMeds recognises this critical decision point by offering transparent pricing and clinical guidance for both options.
The 1.7mg Wegovy equivalent in Mounjaro considerations extend beyond simple dose matching to encompass storage requirements, injection frequency, and individual response patterns. Both treatments require prescription-only medicine status and comprehensive clinical assessment through our GPhC-registered pharmacy. Our pricing structure reflects the complexity of this comparison, with 1.7mg Wegovy priced competitively at £139.99 to ensure accessible treatment options. The decision between continuing with Wegovy's proven semaglutide pathway or transitioning to Mounjaro's dual-agonist approach requires personalised clinical consideration.
Competitive Pricing Structure for 1.7mg Wegovy Treatment
EverydayMeds offers 1.7mg Wegovy at £139.99, representing exceptional value for this penultimate dose before maintenance therapy. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access these competitive prices. Our Elevate Duo bundle combines 1.7mg and 2.4mg doses for £369.99, providing seamless transition planning for patients approaching maintenance. This pricing strategy reflects our commitment to making weight management treatment accessible throughout the dose escalation journey.
The 1.7mg Wegovy equivalent in Mounjaro price comparison reveals significant value advantages with our structured approach. Our Consistency 1.7mg bundle offers two pens for £309.99, ideal for patients requiring extended treatment at this dose level. Discount codes are applied at checkout to reach these final prices, with no hidden costs or additional fees. The transparent pricing model includes clinical assessment, prescriber review, and next-day cold-chain delivery, ensuring comprehensive value beyond medication cost alone.
Clinical Evidence Supporting 1.7mg Wegovy Equivalent Comparisons
The STEP clinical trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved significant weight management outcomes. In STEP 1, participants experienced average weight loss of approximately 15% at 68 weeks, with the 1.7mg dose representing a crucial escalation point towards these results. The evidence base for semaglutide provides robust support for the 1.7mg dosing phase effectiveness.
When considering 1.7mg Wegovy equivalent in Mounjaro options, both treatments have demonstrated efficacy in their respective clinical programmes, though direct head-to-head comparisons are limited due to different trial designs and populations. The STEP trials (Wilding et al., NEJM, 2021) established semaglutide's efficacy profile, whilst separate trials have evaluated tirzepatide's dual-agonist approach. Both Wegovy and Mounjaro are available from EverydayMeds, with your prescriber able to help determine which treatment aligns with your clinical profile and treatment goals.
Mechanism of Action: How 1.7mg Wegovy Functions
Wegovy's active ingredient, semaglutide, functions as a GLP-1 receptor agonist that mimics the natural incretin hormone glucagon-like peptide-1. At the 1.7mg dose level, this mechanism promotes satiety by acting on appetite centres in the brain, potentially reducing food cravings and promoting feelings of fullness after smaller meals. The once-weekly injection schedule maintains consistent therapeutic levels, supporting sustainable weight management alongside a reduced-calorie diet and increased physical activity. This mechanism differs from Mounjaro's dual GIP/GLP-1 approach, providing patients with distinct treatment pathways. The 1.7mg dose represents near-maximum therapeutic benefit for most patients, with only the 2.4mg maintenance dose remaining in the escalation protocol.
Streamlined Ordering Process for 1.7mg Wegovy
Accessing 1.7mg Wegovy through EverydayMeds begins with a comprehensive 3-minute online clinical assessment designed to evaluate your treatment suitability. Our qualified prescribers review applications within 3 working days (or 24 hours with express service), ensuring thorough evaluation of your weight management needs. Upon approval, your prescription-only medicine is dispatched via next-day delivery using specialised cold-chain transport to maintain medication integrity. The process includes automatic follow-up scheduling to support your progression from 1.7mg to the 2.4mg maintenance dose. Our GPhC #9012878 registered pharmacy status ensures compliance with all UK pharmaceutical regulations throughout your treatment journey.
Storage and Practical Considerations for Wegovy Treatment
Wegovy requires refrigerated storage at 2-8°C before first use, with the significant advantage of remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration. This storage flexibility represents a key practical advantage over Mounjaro, which maintains room temperature stability for only 21 days. The FlexTouch pen delivery system ensures precise 1.7mg dosing with user-friendly injection mechanics. Dose escalation from 1mg to 1.7mg follows the mandatory protocol, with patients unable to skip doses due to tolerability and efficacy considerations. The 1.7mg phase typically lasts 4 weeks before progressing to the 2.4mg maintenance dose, though some patients may require extended treatment at this level based on clinical response.
Strategic Treatment Planning: 1.7mg Wegovy vs Mounjaro Decision Framework
The choice between continuing 1.7mg Wegovy or considering Mounjaro equivalent requires evaluation of individual response patterns, storage preferences, and long-term treatment goals. Patients who have successfully progressed through Wegovy's dose escalation to 1.7mg often benefit from treatment continuity, particularly given the proven semaglutide pathway and established tolerance profile. The price advantage of £139.99 for 1.7mg Wegovy, combined with our Elevate Duo transition bundles, supports cost-effective long-term planning.
However, some patients may explore 1.7mg Wegovy equivalent in Mounjaro options due to individual clinical factors or response considerations. The dual GIP/GLP-1 mechanism offers an alternative pathway that may suit different patient profiles, though switching between treatments requires careful clinical oversight. Both options remain available through EverydayMeds, with our clinical team providing personalised guidance based on treatment history, response patterns, and individual preferences. The decision ultimately rests with prescriber recommendation and patient preference, supported by transparent pricing and comprehensive clinical support.
Complete Treatment Access with Competitive Pricing
EverydayMeds combines clinical excellence with market-leading pricing to deliver exceptional value for 1.7mg Wegovy treatment. New customers use code FIRST40 whilst returning customers apply DOSE25 at checkout to access our competitive prices, with bundles available for treatment continuity planning. Your treatment journey includes comprehensive prescriber support, medication counselling, and follow-up scheduling to optimise outcomes. Visit https://everydaymeds.co.uk/products/wegovy-1-7mg to begin your clinical assessment and access the UK's most competitive 1.7mg Wegovy pricing. Both Wegovy and Mounjaro remain available through our GPhC-registered pharmacy, ensuring choice and flexibility throughout your weight management journey alongside a reduced-calorie diet and increased physical activity.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
